Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

One-step cleavage and purification: a bifunctional IdeS-Protein A fusion protein for on-column generation of antibody fragments.

Created on 12 Sep 2026

Authors

Tongsheng Zhang, Huayuan Liao, Chun-Bo Teng, Chao Wang

Published in

mAbs. Volume 18. Issue 1. Pages 2684388. Epub Jun 05, 2026.

Abstract

Conventional production of antibody fragments (e.g. Fab/F(ab')2, VHH/(VHH)2) involves sequential enzymatic cleavage and multi-step purification to remove Fc domains and residual enzymes, a process that is laborious and inefficient for small-scale workflows. To address this, we engineered a bifunctional IdeS-Protein A (IPA) fusion protein, which combines the specific IgG-cleaving activity of IdeS with the Fc-binding capability of Protein A. In solution, this construct enabled simultaneous antibody cleavage and affinity-mediated removal of both the enzyme and Fc fragments in a single step. Furthermore, we immobilized the fusion protein on a chromatographic resin to create an integrated "on-column cleavage-purification" platform. This system allows antibody capture, in-situ cleavage, and direct collection of high-purity F(ab')2 fragments from the flow-through, while Fc fragments, uncleaved antibodies, and the enzyme are retained on the column. This work establishes a streamlined, one-step method for generating antibody fragments, offering a robust and automatable platform for research and preclinical applications.

PMID:
42246413
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement